SCHEMBL3003296

SCHEMBL3003296

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 12/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
F2RL3 Q96RI0 1/20 0.32
HTR6 P50406 1/20 0.31
GBA1 P04062 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016578 0.93 OGA (0.33) DNM1LSMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3010354 0.92 DNM1L (0.34) DNM1LF2RL3HTR6HRH3
SCHEMBL3018237 0.92 AOC3 (0.33) DNM1LSMN1; SMN2NPC1RAB9AF2RL3
SCHEMBL3012892 0.92 DNM1L (0.32) DNM1LSMN1; SMN2NPC1RAB9AF2RL3
SCHEMBL3012451 0.91 MAPT (0.34) SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3013236 0.91 NPC1 (0.36) DNM1LSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3014778 0.91 DNM1L (0.33) DNM1LSMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3014046 0.91 F2RL3 (0.37) SMN1; SMN2NPC1RAB9AALDH1A1POLB
SCHEMBL3008790 0.90 CACNA1G (0.33) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3011686 0.89 MAPT (0.35) SMN1; SMN2NPC1RAB9AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885SMN1; SMN2 1/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.